OnDose is a simple blood test that helps oncologists to optimize infusional 5-FU therapy on an individual basis. OnDose provides the data for pharmacokinetically-guided dose adjustments of infusional 5-FU to help optimize dosing for patients with colorectal cancer.
In a phase 3, multicenter, randomized study (N=208), optimized dosing demonstrated proven benefits for both efficacy and toxicity.1
- Provided significantly greater objective response rates (33.7% versus 17.3% with body surface area [BSA]-based dosing; P=.004)1
- Despite having higher mean doses of 5-FU,* patients experienced significantly less toxicity (P=.003)1
- Optimized dosing demonstrated a trend toward increased median survival1
- 22 months versus 16 months with BSA-based dosing (P=.08)1
With OnDose, dosing can be as individual as your patients
The OnDose Results Report is designed to provide you with an accurate and timely measurement of infusional 5-FU exposure in patients with colorectal cancer. The test results are used to help optimize an individualized dose for the next cycle and help guide your patients' doses into a clinically established target area under the curve range (20-24 mg•h/L).